Moderna pays up to $2.25bn to settle drug delivery tech patent lawsuit
Moderna has agreed to pay up to $2.25bn to settle a patent infringement lawsuit with Genevant and Arbutus, ending a …
Post
-
-
Targeted therapies to join chemo as oncology treatment backbone
In recent years, the oncology sector has undergone a fundamental shift away from chemotherapy-dominant treatment towards the use of regimens …
-
CordenPharma leases space at Flatiron Park for peptides development
US-based CordenPharma Colorado has leased a 64,000ft² space at BioMed Realty’s Flatiron Park’s 5505 Central, which marks Boulder’s first purpose-built …
-
Pharmaceutical Technology’s parent company GlobalData moves to Main Market of LSE
LONDON, 05 March 2026 – GlobalData Plc, the trusted intelligence platform and parent company of Pharmaceutical Technology, today moves from AIM to the Main Market of the …
-
Affinia receives FDA fast track designation for AFTX-201
Affinia Therapeutics has received the US Food and Drug Administration (FDA) fast track designation (FTD) for AFTX-201, a genetic medicine …
-
Sanofi bets on Sino Biopharm’s transplant drug in $1.5bn licensing deal
Sanofi has taken a chance on Sino Biopharmaceutical’s first-in-class, anti-inflammatory and anti-fibrotic asset, rovadicitinib, through a licensing agreement worth up …
-
Aspire Biopharma and Microsize collaborate for alprazolam powder formulation
Aspire Biopharma has entered a strategic partnership with Microsize to advance the development of a new sublingual powder formulation of …
-
Esperion to acquire Corstasis for cardiovascular franchise expansion
Esperion Therapeutics has signed a definitive agreement to acquire Corstasis Therapeutics to expand its cardiovascular franchise with the addition of …
-
Extracellular vesicles: The next frontier in regenerative medicine and drug delivery?
Extracellular vesicles (EVs) are tiny, membrane-bound particles released by every cell type studied to date. Though small, they carry a …
-
Navigating uncertainty and building resilient supply chains: The case for US-based CDMO partnerships
Choosing to onshore pharmaceutical manufacturing by partnering with a US-based contract development and manufacturing organization (CDMO) can offer advantages for …
-
OSE narrows pipeline focus amid Boehringer MASH collaboration retreat
French biotech OSE Therapeutics has shifted focus to its later-stage clinical assets as it looks to prioritise near-term value creation. OSE’s …
-
Pharma rings the changes as CEO shake-up continues
Bavarian Nordic’s announcement that Paul Chaplin will step down as CEO has marked the latest high-profile change at a pharmaceutical …
-
Europe’s pharma trade with the US remains critical despite tariff turmoil
US government policies of Most Favored Nation (MFN) and tariffs threaten to disrupt Europe’s pharmaceutical trade, but while European countries …
-
Rallybio to acquire Candid Therapeutics
US-based biotechnology company Rallybio has entered a definitive agreement to acquire Candid Therapeutics through a merger transaction. Following completion, the combined …
-
Novo Nordisk starts €432m Ireland facility upgrade for oral Wegovy production
Novo Nordisk has invested €432m ($501m) to upgrade its facility in Ireland to ensure the drugmaker can meet the anticipated …
